Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT-419B in Advanced Breast Cancer
NCT05304962Phase 1Recruiting
- Sponsor
- Regor Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GDC-4198 in breast cancer (2 arms), sponsored by Regor Therapeutics. Primary endpoint: Dose-Limiting Toxicities at 4 weeks. Started Mar 2022; status: recruiting.
02
Drugs
GDC-4198
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05304962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304962.